New Biomarkers in Axial Sypondyloarthropathy; SII and SIRI

In Patients With Axial Spondyloarthropathy; Evaluation of the Relationship Between the Systemic Immune Inflammation Index and the Systemic Inflammatory Response Index With Disease Activity and Function

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05914532

Enrollment

155

Registered

2023-06-22

Start date

2023-06-22

Completion date

2023-08-10

Last updated

2023-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Axial Spondyloarthritis

Keywords

Axial Spondyloarthritis, Systemic Immune Inflammation Index, Systemic Inflammation Response Index

Brief summary

investigators aimed to evaluate the relationship between Systemic Immune Inflammation Index (SII) and Systemic Inflammation Response Index (SIRI) and disease activity in patients with axial spondyloarthropathy (SpA).

Detailed description

The clinical characteristics and laboratory data of the patients and healthy controls participating in our study were obtained through the hospital system. Then, the new biomarkers SIRI and SII values were calculated. SIRI= neutrophil count\*monocyte count/lymphocyte count and SII= neutrophil count\*platelet count/lymphocyte count. Then, SIRI and SII values were compared between groups. The relationship between disease activity and SIRI and SII values in the patient group was examined.

Interventions

OTHERlab testing

Complete blood count and erythrocyte sedimentation rate and C-reactive protein values of the participants were analyzed by laboratory test.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* SpA patients diagnosed according to the 2009 Assessment of Spondyloarthritis International Society classification criteria * 51 healthy controls working in our hospital,

Exclusion criteria

infections, coronary artery disease, kidney and liver dysfunction, cancer diagnosis, surgery in the last three months, diabetes mellitus diagnosis, hypertension and pregnant women

Design outcomes

Primary

Measure	Time frame	Description
Comparison of SIRI and SII between Patient and Healthy Control	Baseline	SIRI= neutrophil count\monocyte count/lymphocyte count and SII= neutrophil count\platelet count/lymphocyte count.

Secondary

Measure	Time frame	Description
Correlation analysis of SIRI and SII with scales and laboratory findings	Baseline	SIRI= neutrophil count\monocyte count/lymphocyte count and SII= neutrophil count\platelet count/lymphocyte count.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026